Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs

Bioconjugate Chemistry

Volumn 27, Issue 9, 2016, Pages 2081-2088

  Kern, Jeffrey C ^a   Dooney, Deborah ^a   Zhang, Rena ^a   Liang, Linda ^a   Brandish, Philip E ^b   Cheng, Mangeng ^a   Feng, Guo ^a   Beck, Andrew ^c   Bresson, Damien ^c   Firdos, Juhi ^c   Gately, Dennis ^c   Knudsen, Nick ^c   Manibusan, Anthony ^c   Sun, Ying ^c   Garbaccio, Robert M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Respiratory and Immunology Biology   (United States)

^c AMBRX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; CELL CULTURE; CONTROLLED DRUG DELIVERY; HORMONES; TARGETED DRUG DELIVERY;

ALIPHATIC ALCOHOL; ANTIBODY-DRUG CONJUGATES; AQUEOUS SOLUBILITY; CATHEPSIN B; GLUCOCORTICOIDS; RAPID RELEASE; SITE-SPECIFIC; SMALL-MOLECULE DRUGS; SOLUBLE PHOSPHATES; TARGETED DELIVERY;

PLASMA STABILITY;

ALKANOL; ANTIBODY DRUG CONJUGATE; BUDESONIDE; CATHEPSIN B; CD70 ANTIGEN; CITRULLINE; DRUG CARRIER; GLUCOCORTICOID; GLUCOCORTICOID INDUCED LEUCINE ZIPPER; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; PHOSPHATE; PHOSPHORAMIDOUS ACID; UNCLASSIFIED DRUG; VALINE; ALCOHOL DERIVATIVE; ANTIBODY CONJUGATE; CARBONIC ACID DERIVATIVE; WATER;

AQUEOUS SOLUTION; ARTICLE; CARCINOMA; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LYSOSOME; CHEMISTRY; METABOLISM; SOLUBILITY;

ALCOHOLS; CARBONATES; CATHEPSIN B; DRUG STABILITY; HUMANS; IMMUNOCONJUGATES; LYSOSOMES; PHOSPHATES; SOLUBILITY; WATER;

EID: 84988642872     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.6b00337     Document Type: Article

References (15)

1. Senter, P. D. and Sievers, E. L. (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Nat. Biotechnol. 30, 631-637 10.1038/nbt.2289
2. Li, Y., Gu, C., Gruenhagen, J., Yehl, P., Chetwyn, N. P., and Medley, C. D. (2016) An enzymatic deconjugation method for the analysis of small molecule active drugs on antibody-drug conjugates MAbs. 8, 698-705 10.1080/19420862.2016.1151590
3. Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., and Trail, P. A. (2002) Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity Bioconjugate Chem. 13, 855-869 10.1021/bc025536j
4. Elgersma, R. C., Coumans, R. G. E., Huijbregts, T., Menge, W., Joosten, J. A. F., Spijker, H. J., de Groot, F. M. H., van der Lee, M. M. C., Ubink, R., and van den Dobbelsteen, D. J. et al. 2015, Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985 Mol. Pharmaceutics 12, 1813-1835 10.1021/mp500781a
5. Buttgereit, F., Spies, C. M., and Bijlsma, J. W. (2015) Novel glucocorticoids: where are we now and where do we want to go? Clin. Exp. Rheumatol. 33, S29-33
6. O'Connell, E. J. (2002) Efficacy of budesonide in moderate to severe asthma Clin. Ther. 24, 887-905 10.1016/S0149-2918(02)80005-4
7. Dubowchik, G. M., Mosure, K., Knipe, J. O., and Firestone, R. A. (1998) Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol®), mitomycin C and doxorubicin Bioorg. Med. Chem. Lett. 8, 3347-3352 10.1016/S0960-894X(98)00610-6
8. Dubowchik, G. M. and Firestone, R. A. (1998) Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin Bioorg. Med. Chem. Lett. 8, 3341-3346 10.1016/S0960-894X(98)00609-X
9. Kern, J. C., Cancilla, M., Dooney, D., Kwasnjuk, K., Zhang, R., Beaumont, M., Figueroa, I., Hsieh, S., Liang, L., and Tomazela, D. et al. 2016, Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody-Drug Conjugates J. Am. Chem. Soc. 138, 1430-1445 10.1021/jacs.5b12547
10. Bertozzi, C. R., Agard, N. J., Prescher, J. A., Baskin, J. M., and Sletten, E. M. (2009) Preparation of cyclooctynes and azacyclooctynes for modification of biomolecules in vivo and in vitro by their copper-free strain-promoted [3 + 2] cycloaddition with azides. US Patent No 7,807,619.
11. Cho, H. S., Daniel, T. O., Wilson, T. E., Cujec, T. P., Tian, F., Hays, A.-M., Kimmel, B. E., and Ho, L. (2006) Antibodies with increased serum half-life and protease resistance prepared by polynucleotides encoding selector codon, orthogonal RNA synthetase and orthogonal tRNA. US Patent 7,632,924.
12. Agard, N. J., Baskin, J. M., Prescher, J. A., Lo, A., and Bertozzi, C. R. (2006) A Comparative Study of Bioorthogonal Reactions with Azides ACS Chem. Biol. 1, 644-648 10.1021/cb6003228
13. McDonagh, C. F., Kim, K. M., Turcott, E., Brown, L. L., Westendorf, L., Feist, T., Sussman, D., Stone, I., Anderson, M., and Miyamoto, J. et al. 2008, Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index Mol. Cancer Ther. 7, 2913-2923 10.1158/1535-7163.MCT-08-0295
14. Jeffrey, S. C., Burke, P. J., Lyon, R. P., Meyer, D. W., Sussman, D., Anderson, M., Hunter, J. H., Leiske, C. I., Miyamoto, J. B., and Nicholas, N. D. et al. 2013, A Potent Anti-CD70 Antibody-Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology Bioconjugate Chem. 24, 1256-1263 10.1021/bc400217g
15. Adam, P. J., Terrett, J. A., Steers, G., Stockwin, L., Loader, J. A., Fletcher, G. C., Lu, L.-S., Leach, B. I., Mason, S., and Stamps, A. C. et al. 2006, CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding Br. J. Cancer 95, 298-306 10.1038/sj.bjc.6603222